Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2015–2019

MOGLYNET · Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2015-09-01 → 2019-11-30
Финансиране от ЕС
3 086 436 €
Участници
13
Схема
MSCA-ITN-EJD

Линиите свързват координатора с партньорите.

Накратко на български

Нови химични съединения влияят върху ензима PFKFB3, за да се контролира образуването на нови кръвоносни съдове при атеросклерозата. Това може да забави растежа на плаките в артериите и да намали риска от инфаркти и инсулти.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study

The mission of Moglynet has been to define a joint doctoral educational training model in Drug Discovery and Development where Academia and Industry, supported by other institutions and organizations, joined their forces to create a common knowledge and language for future researchers working in the Pharma-field. The scientific activity was focused on atherosclerotic cardiovascular disease, which is an age-related major cause of death in the western world. Thanks to cholesterol-lowering drugs, the lifespan and wellbeing of patients have significantly improved, however, a large group of patients does not fully benefit from current pharmacological intervention. Our aim has been to find a new strategy to control neo-vessel formation in the atherogenic process. To reach this goal, a multidisciplinary consortium was created, bringing together researchers with different expertice (drug design, synthesis of new molecules, cell metabolism, angiogenesis, cardiovascular diseases and imaging technologies). The Consortium worked synergistically to design and develop new compounds for modulating the activity of a glycolytic flux enzyme, i.e. PFKFB3, as a new potential target for atherosclerosis. As a result, progression of atherosclerotic plaque growth and their rupture could be prevented, and consequently the occurrence of acute cardiovascular events such as myocardial infarctions and strokes may be reduced. This PhD research program has been uniquely articulated as compared to the traditional doctoral courses s, where each graduate student pursues an individual research project, unrelated to that of other students. The multidisciplinary context of the MOGLYNET doctorate provided our 12 Early Stage Researchers (ESRs) a holistic view on different research approaches to the same overarching research question. The contribution of the seven industrial partners belonging to the Consortium has been of fundamental importance in equipping our ESRs with a strengthened and complementary entrepreneurial culture.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry join their forces for:- creating a common platform of knowledge and language for early stage researchers (ESR) working in the Drug Discovery and Development area aiming to convey complementary pharma-skills- exploiting this platform to train a new generation of cutting-edge researchers and professionals highly attractive for employment by the European Pharma-industry- establishing structures for long-term cooperation, strengthening the relationships among the leading Universities and Pharma-enterprises and to continuously develop the research training platform that European industry relies on.To achieve the above objectives the main tasks of MoGlyNet are:- to attract/train 12 ESRs in optimization joint academic/industrial program of cutting-edge training-by-research, high quality supervision, complementary and transferable Pharma-skills training, inter-network secondments, and workshops/Summer Schools- to pursue an innovative research project that will tackle a timely and important scientific problem with a multidisciplinary approach (from molecular modelling to in vivo studies). Atherosclerosis is an aging-related disease and our research approach for a better therapy of atherosclerosis will be focused on the PFKFB3 enzyme, a key player in glycolysis/oxidative stress and therefore in pathological angiogenesis - to build a solid foundation for long-term European excellence in this field by disseminating MoGlyNet research/training outcomes and best practice into the partners Doctoral Schools, and by fostering long-term partnerships and collaborations that will outlast the Consortium- to transfer expertise/know-how among the Consortium participants and to external groups via networking activities, intersectorial exposure, secondments, workshops, sharing of learning material, public engagement and outreach activities

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз